Welcome, Guest. Please login or register.
December 26, 2024, 02:50:26 am

Login with username, password and session length


Members
  • Total Members: 6315
  • Latest: DRG
Stats
  • Total Posts: 55137
  • Total Topics: 4855
  • Online Today: 194
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 167
Total: 167

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Approves First-Ever Drug for Fatty Liver Disease  (Read 1457 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 191
FDA Approves First-Ever Drug for Fatty Liver Disease
« on: December 09, 2024, 10:40:52 am »
On March 14, the Food and Drug Administration (FDA) granted accelerated approval of Madrigal Pharmaceuticals’ resmetirom (brand name Rezdiffra) as the first medication for metabolic dysfunction-associated steatohepatitis (MASH), or advanced fatty liver disease.

Resmetirom, a once-daily pill, was approved along with diet and exercise for adults with MASH who have moderate to advanced (Stage F2 or F3) liver fibrosis but have not yet progressed to cirrhosis (Stage F4). Patients will not need a liver biopsy to be eligible for the new treatment. The approval is supported by results from a late-stage clinical trial which showed that resmetirom is the first drug to both reduce liver fat accumulation and improve fibrosis.

Read more...
https://www.hepmag.com/article/fda-approves-firstever-drug-fatty-liver-disease

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.